IndustryCompany release

Bioventus Q3 revenue up 3% as it trims sales guidance and continues strategic review

🇺🇸 Bioventus Inc. (BVS) · Mon 02 Nov 2026

The Nasdaq-listed medtech reported $6.0 million net income, prepaid $15 million of its term loan and updated 2026 net sales guidance to $590-595 million.

Bioventus (Nasdaq: BVS) published results for the quarter ended 26 September 2026 on 2 November, reporting a 3% rise in revenue. The headline figure, according to the company's announcement, was $142.4 million.

Growth was led by the Pain Treatments business, which includes products such as Durolane. Net income for the quarter was $6.0 million.

On the balance sheet, the company made a $15 million prepayment on its term loan. It also reaffirmed its adjusted earnings-per-share guidance for the year, while updating its 2026 net sales guidance to a range of $590-595 million.

Bioventus said it is still reviewing strategic alternatives. The summary available to VigiEye gave no further detail on the scope, timing or possible outcomes of that review, and the full release text was not available for this report.

What it means for your team

  • Market-access teams tracking Pain Treatments should note that Durolane was named among the products driving growth in the quarter.
  • The ongoing strategic alternatives review may bring uncertainty for partners, suppliers and customers; no outcomes have been disclosed.
  • The updated net sales range of $590-595 million gives a reference point for monitoring the company's full-year performance.

Company's press release (SEC filing): Bioventus Inc. ↗

Article written by VigiEye from the official source (Bioventus Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →